ES2735411T3 - Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina - Google Patents

Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina Download PDF

Info

Publication number
ES2735411T3
ES2735411T3 ES16163733T ES16163733T ES2735411T3 ES 2735411 T3 ES2735411 T3 ES 2735411T3 ES 16163733 T ES16163733 T ES 16163733T ES 16163733 T ES16163733 T ES 16163733T ES 2735411 T3 ES2735411 T3 ES 2735411T3
Authority
ES
Spain
Prior art keywords
triazol
phenyl
fluoro
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16163733T
Other languages
English (en)
Spanish (es)
Inventor
Wenying Chai
Michael LETAVIC
Kiev Ly
Daniel Pippel
Dale Rudolph
Kathleen Strother
Brad Savall
Chandravadan Shah
Brock Shireman
Akinola Soyode-Johnson
Emily Stocking
Devin Swanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2735411T3 publication Critical patent/ES2735411T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES16163733T 2009-10-23 2010-10-21 Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina Active ES2735411T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25450909P 2009-10-23 2009-10-23

Publications (1)

Publication Number Publication Date
ES2735411T3 true ES2735411T3 (es) 2019-12-18

Family

ID=43385633

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16163733T Active ES2735411T3 (es) 2009-10-23 2010-10-21 Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
ES10773477.4T Active ES2585806T3 (es) 2009-10-23 2010-10-21 Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10773477.4T Active ES2585806T3 (es) 2009-10-23 2010-10-21 Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina

Country Status (38)

Country Link
US (8) US8653263B2 (OSRAM)
EP (3) EP2491038B1 (OSRAM)
JP (1) JP5759470B2 (OSRAM)
KR (3) KR101859400B1 (OSRAM)
CN (1) CN102781942B (OSRAM)
AR (2) AR078731A1 (OSRAM)
AU (2) AU2010310595B2 (OSRAM)
BR (1) BR112012010820B1 (OSRAM)
CA (1) CA2778484C (OSRAM)
CL (1) CL2010001162A1 (OSRAM)
CO (1) CO6541572A2 (OSRAM)
CR (1) CR20120273A (OSRAM)
CY (2) CY1117743T1 (OSRAM)
DK (2) DK3093291T3 (OSRAM)
EA (1) EA022766B1 (OSRAM)
EC (1) ECSP12011908A (OSRAM)
ES (2) ES2735411T3 (OSRAM)
HR (2) HRP20160781T1 (OSRAM)
HU (2) HUE043962T2 (OSRAM)
IL (1) IL219234A (OSRAM)
JO (2) JO3267B1 (OSRAM)
LT (1) LT3093291T (OSRAM)
ME (2) ME02437B (OSRAM)
MX (1) MX2012004753A (OSRAM)
NI (1) NI201200062A (OSRAM)
NZ (1) NZ599629A (OSRAM)
PE (1) PE20110404A1 (OSRAM)
PH (1) PH12012500796A1 (OSRAM)
PL (2) PL3093291T3 (OSRAM)
PT (2) PT3093291T (OSRAM)
RS (2) RS59004B1 (OSRAM)
SI (2) SI3093291T1 (OSRAM)
SM (2) SMT201900392T1 (OSRAM)
TR (1) TR201910327T4 (OSRAM)
TW (1) TWI481613B (OSRAM)
UA (1) UA107812C2 (OSRAM)
UY (1) UY32966A (OSRAM)
WO (1) WO2011050198A1 (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653263B2 (en) * 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
KR101676930B1 (ko) 2011-11-08 2016-11-16 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 ２-(１,２,３-트리아졸-２-일)벤즈아미드 및 ３-(１,２,３-트리아졸-２-일)피콜린아미드 유도체
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ES2672732T3 (es) 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
MY169986A (en) 2012-06-04 2019-06-19 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
CA2882132C (en) * 2012-08-16 2021-07-06 The Scripps Research Institute Kappa opioid ligands
AR092955A1 (es) 2012-10-10 2015-05-06 Actelion Pharmaceuticals Ltd Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
CN103012293A (zh) * 2012-12-13 2013-04-03 同济大学 一种抗失眠药物mk-4305中间体的合成方法
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
MX2015017961A (es) * 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
JP6421185B2 (ja) 2013-12-04 2018-11-07 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ベンゾイミダゾール−プロリン誘導体の使用
WO2016020403A1 (en) * 2014-08-04 2016-02-11 Sandoz Ag Preparation of a benzoic acid derivative and its use for the preparation of suvorexant
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
EP3191468B1 (en) 2014-09-11 2018-12-12 Janssen Pharmaceutica NV Substituted 2-azabicycles and their use as orexin receptor modulators
AU2016295693B2 (en) 2015-07-17 2020-05-21 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
CN106749269B (zh) * 2015-11-23 2019-01-04 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
WO2017088731A1 (zh) * 2015-11-24 2017-06-01 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
TWI710557B (zh) 2016-02-12 2020-11-21 美商伊歐拉斯治療學公司 作為食慾素受體調節劑之經鹵素取代之六氫吡啶
BR112018067906A2 (pt) * 2016-03-10 2019-01-29 Janssen Pharmaceutica Nv métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
CN105949203B (zh) * 2016-05-24 2018-07-13 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
CN107759620B (zh) * 2016-08-16 2021-11-12 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN108299437B (zh) * 2017-01-13 2022-07-08 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
GB201702174D0 (en) * 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists
PT3619199T (pt) 2017-05-03 2021-10-01 Idorsia Pharmaceuticals Ltd Preparação de derivados de ácido 2-([1,2,3]triazol-2-il)- benzoico
GB201707504D0 (en) * 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
GB201707499D0 (en) * 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
US11161856B2 (en) 2017-08-29 2021-11-02 H. Lundbeck A/S Spirocycle compounds and methods of making and using same
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
EP3668864B1 (en) 2017-09-28 2021-07-21 Boehringer Ingelheim International GmbH N-(2,2-difluoroethyl)-n-[(pyrimidinylamino)propanyl]arylcarboxamides
CN109988169B (zh) * 2017-12-29 2022-02-01 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109988171A (zh) * 2017-12-29 2019-07-09 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109988170B (zh) * 2017-12-29 2022-04-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
WO2020023723A1 (en) * 2018-07-27 2020-01-30 Icahn School Of Medicine At Mount Sinai Method of treating aggression with orexin receptor antagonists
US12030887B2 (en) * 2018-11-14 2024-07-09 Janssen Pharmaceutica Nv Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN112142713A (zh) * 2019-06-27 2020-12-29 山东润博生物科技有限公司 一种咪草烟的合成方法
KR20220044323A (ko) * 2019-08-07 2022-04-07 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 (2h-1,2,3-트라이아졸-2-일)페닐 화합물을 제조하는 개선된 합성 방법
CN112876481B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
CN112876477B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
CN112876479B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
CN112876478B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
CN112876480B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
WO2022122009A1 (zh) * 2020-12-11 2022-06-16 苏州晶云药物科技股份有限公司 吡咯类衍生化合物的晶型及其制备方法
TW202246274A (zh) * 2021-03-16 2022-12-01 大陸商上海翰森生物醫藥科技有限公司 含氮雜環的多環化合物及其製備方法和應用
CN114063673B (zh) * 2021-11-09 2023-03-03 万华化学集团股份有限公司 一种反应釜温度控制方法、系统及存储介质
CN116217593B (zh) * 2021-12-02 2025-05-09 江苏恩华药业股份有限公司 一种八氢吡咯并[3,4-c]吡咯甲基酮衍生物及其应用
US20250154158A1 (en) 2022-02-24 2025-05-15 Teva Czech Industries S.R.O. Solid state forms of seltorexant
WO2023180556A1 (en) * 2022-03-24 2023-09-28 Janssen Pharmaceutica Nv Methods for treating agitation in subjects with mild cognitive impairment or major neurocognition disorder
UY40353A (es) * 2022-07-15 2024-01-31 Biogen Ma Inc Inhibidores de proteína de unión a emopamil y usos de estos
CN119866339A (zh) * 2022-09-14 2025-04-22 江苏豪森药业集团有限公司 含氮杂环的多环化合物的自由碱晶型及其制备方法
JP2025507883A (ja) * 2022-11-23 2025-03-21 チアンスー エヌエイチダブリュエー ファーマシューティカル カンパニー リミテッド 二置換オクタヒドロピロロ［３，４－ｃ］ピロールメチルケトン誘導体及びその使用
EP4635949A1 (en) * 2022-12-12 2025-10-22 Jiangsu NHWA Pharmaceutical Co., Ltd Substituted tetrahydrocyclopentyl[c]pyrrole derivative, preparation method, intermediate and use thereof
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators
WO2025003991A1 (en) 2023-06-29 2025-01-02 Janssen Pharmaceutica Nv Method of treating depression using seltorexant
WO2025162233A1 (zh) * 2024-01-29 2025-08-07 成都康弘药业集团股份有限公司 食欲素受体调节剂及其制备方法和用途
WO2025242852A1 (en) 2024-05-24 2025-11-27 Janssen Pharmaceutica Nv Seltorexant for use in treating major depressive disorder with insomnia symptoms
CN118580243B (zh) * 2024-08-07 2025-01-03 艾斯拓康生物医药(天津)有限公司 一类含氮并环化合物及其制备方法和应用
CN119039301B (zh) * 2024-10-31 2025-09-02 江苏豪森药业集团有限公司 一种含氮杂环的多环化合物晶型ⅰ的制备方法

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
JPH11510478A (ja) 1995-06-06 1999-09-14 アボツト・ラボラトリーズ キノリジノン型化合物
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
AU3555200A (en) 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
US6375897B1 (en) 2000-02-14 2002-04-23 Ansys Technologies, Inc. Urine collection cup
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
WO2001085693A1 (en) 2000-05-11 2001-11-15 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
SE0100326D0 (sv) 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
WO2002070527A1 (en) 2001-03-02 2002-09-12 Akzo Nobel N.V. Mass-selective purification of organometallics
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
BR0210609A (pt) 2001-06-28 2004-07-20 Smithkline Beecham Plc Derivados de amina cìclica n-aroila como antagonistas do receptor da orexina
US6455722B1 (en) 2001-06-29 2002-09-24 Pabu Services, Inc. Process for the production of pentaerythritol phosphate alcohol
GB2383315B (en) 2001-12-18 2005-04-06 Christopher Donald Clarke Vehicle imaging system
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
DE10226943A1 (de) 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
CN1556705B (zh) * 2002-07-09 2010-04-28 埃科特莱茵药品有限公司 7,8,9,10-四氢-6H-氮杂卓并、6,7,8,9-四氢-吡啶并和2,3-二氢-2H-吡咯并[2,1-b]-喹唑啉酮衍生物
KR20050043988A (ko) 2002-10-11 2005-05-11 액테리온 파마슈티칼 리미티드 설포닐아미노-아세트산 유도체 및 오렉신 수용체길항제로서 이들의 용도
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
CN100432056C (zh) 2003-03-26 2008-11-12 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
WO2004096780A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Quinoxalinone-3- one derivatives as orexin receptor antagonists
US20040242641A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
WO2005005439A1 (en) 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2005023231A1 (en) 2003-09-10 2005-03-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
JP5646126B2 (ja) 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
CA2558211C (en) 2004-03-03 2013-09-03 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP5153329B2 (ja) 2004-07-22 2013-02-27 カムブァ、アイピー、ヴェンチュァズ、エル、ピー （ｒ／ｓ）リファマイシン誘導体、その調製、および医薬組成物
EP1778688A1 (en) 2004-07-22 2007-05-02 Glaxo Group Limited Antibacterial agents
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
JP2008519078A (ja) 2004-11-04 2008-06-05 ニューロゲン コーポレイション Ｃｂ１拮抗薬としてのアリールアルキル尿素類
WO2006056848A1 (en) 2004-11-24 2006-06-01 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
DE102004061344A1 (de) 2004-12-20 2006-07-06 Siemens Ag Verfahren zur sicheren Auslegung eines Systems, zugehörige Systemkomponente und Software
US20060258691A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
WO2006124748A2 (en) * 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Multicyclic compounds and methods of their use
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
US20080175795A1 (en) 2005-06-30 2008-07-24 Bexel Pharmaceuticals, Inc. Novel derivatives of amino acids for treatment of obesity and related disorders
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
WO2007025069A2 (en) 2005-08-26 2007-03-01 Merck & Co., Inc. Diazaspirodecane orexin receptor antagonists
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20090105318A1 (en) 2006-03-29 2009-04-23 Coleman Paul J Amidoethylthioether Orexin Receptor Antagonists
EP2001485B1 (en) 2006-03-29 2015-09-09 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
CN101432285A (zh) 2006-04-26 2009-05-13 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的吡唑并-四氢吡啶衍生物
WO2007146761A2 (en) 2006-06-12 2007-12-21 Neurogen Corporation Diaryl pyrimidinones and related compounds
AU2007272795A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
AU2007272855B2 (en) 2006-07-14 2013-08-01 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
US7994336B2 (en) 2006-08-15 2011-08-09 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
DE602007004999D1 (de) 2006-08-28 2010-04-08 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
DE602007007497D1 (de) 2006-09-18 2010-08-12 Hoffmann La Roche Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008067121A2 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
BRPI0720522A2 (pt) 2006-12-22 2014-01-07 Actelion Pharmaceuticals Ltd Composto derivado de 5,6,7,8-tetra-hidroimidazo [1,5-a] pirazina e uso deste ou de um de seus sais farmaceuticamente aceitáveis.
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
US8106215B2 (en) 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
EA201070091A1 (ru) 2007-07-03 2010-06-30 Глэксо Груп Лимитед Производные пиперидина, пригодные в качестве антагонистов рецептора орексина
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009011775A1 (en) 2007-07-13 2009-01-22 Merck & Co., Inc. Amidoethyl alkylamino orexin receptor antagonists
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US8288429B2 (en) 2007-07-27 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.3.0]octane derivatives
BRPI0814767A2 (pt) 2007-08-02 2015-03-03 Hoffmann La Roche Derivados de monoamida como antagonistas do receptor de orexina
MX2010001575A (es) 2007-08-15 2010-03-15 Actelion Pharmaceuticals Ltd Derivados de 1,2-diamido-etileno como antagonistas de orexina.
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
US8362009B2 (en) 2007-10-29 2013-01-29 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
DE102007052177A1 (de) 2007-10-30 2009-05-07 Novega Produktionssysteme Gmbh Ortungsbake
EP2058001A1 (en) 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
CN101903372B (zh) 2007-12-21 2014-06-18 弗·哈夫曼-拉罗切有限公司 作为食欲肽受体拮抗剂的杂芳基衍生物
EA017144B1 (ru) 2007-12-21 2012-10-30 Астразенека Аб N-содержащие бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
MX377802B (es) 2008-05-27 2025-03-11 Intra Cellular Therapies Inc Metodos y composiciones para trastornos del sueño y otros trastornos.
KR101359852B1 (ko) 2008-07-29 2014-02-06 에프. 호프만-라 로슈 아게 오렉신 길항제로서 피롤리딘-3-일메틸-아민
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
US20100267730A1 (en) 2008-10-09 2010-10-21 Giuseppe Alvaro Novel compounds
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
CA2739919A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
US8623863B2 (en) 2008-10-21 2014-01-07 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
EP2349269A4 (en) 2008-10-21 2012-04-25 Merck Sharp & Dohme 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
CA2739917A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
WO2010048010A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2350061B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
BRPI0919876A8 (pt) 2008-10-30 2016-02-10 Merck Sharp & Dohme Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
CA2741648A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
WO2010051238A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
UY32277A (es) 2008-12-02 2010-05-31 Glaxo Group Ltd Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US20100214135A1 (en) 2009-02-26 2010-08-26 Microsoft Corporation Dynamic rear-projected user interface
MX2011011127A (es) 2009-04-24 2011-11-18 Glaxo Group Ltd 3-azabiciclo[4.1.0] heptanos usados como antagonistas de orexina.
WO2011023578A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
US20120149711A1 (en) 2009-08-24 2012-06-14 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US8653263B2 (en) 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
EP2491019B1 (en) 2009-10-24 2016-06-29 Indiana University Research and Technology Corporation Methods and compositions for panic disorders
TWI410630B (zh) 2009-11-10 2013-10-01 Ct Lab Inc 一種用以治療與食慾素受體１、食慾素受體２、體抑素受體２或多巴胺ｄ２ｌ受體相關之疾病的方法和組合物
CN102884062B (zh) 2009-12-23 2016-08-03 嘉世高制药公司 氨基嘧啶激酶抑制剂
TW201307320A (zh) 2010-12-17 2013-02-16 大正製藥股份有限公司 吡唑衍生物
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
JPWO2012153729A1 (ja) 2011-05-10 2014-07-31 大正製薬株式会社 ヘテロ芳香環誘導体
WO2013005755A1 (ja) 2011-07-05 2013-01-10 大正製薬株式会社 メチルピペリジン誘導体
WO2013059163A1 (en) 2011-10-21 2013-04-25 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ES2672732T3 (es) 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
EP3321257A1 (en) 2012-02-23 2018-05-16 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP2014015452A (ja) 2012-06-15 2014-01-30 Taisho Pharmaceutical Co Ltd ピラゾール誘導体を含有する医薬
KR20150023390A (ko) 2012-06-15 2015-03-05 다이쇼 세이야꾸 가부시끼가이샤 분지쇄 알킬 헤테로 방향환 유도체
EP2862860B1 (en) 2012-06-15 2016-12-21 Taisho Pharmaceutical Co., Ltd. 1,3-oxazolidine or 1,3-oxazinane compounds as orexin receptor antagonists
JP2014111586A (ja) 2012-11-09 2014-06-19 Taisho Pharmaceutical Co Ltd ヘテロ芳香環誘導体を含有する医薬
WO2014085208A1 (en) 2012-11-27 2014-06-05 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
JP2016028017A (ja) 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2014141480A (ja) 2012-12-28 2014-08-07 Taisho Pharmaceutical Co Ltd メチルピペリジン誘導体を含有する医薬
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
WO2015018027A1 (en) 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Thiazole orexin receptor antagonists
CA3205777A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
US9586934B2 (en) 2013-12-09 2017-03-07 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-methyl orexin receptor antagonists
JP5930010B2 (ja) 2013-12-13 2016-06-08 大正製薬株式会社 ヘテロ芳香環メチル環状アミン誘導体を含有する医薬
JP2015131802A (ja) 2013-12-13 2015-07-23 大正製薬株式会社 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬
WO2015095108A1 (en) 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Thioether-piperidinyl orexin receptor antagonists
WO2015123355A1 (en) 2014-02-12 2015-08-20 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
JP2017100951A (ja) 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
JP2017100950A (ja) 2014-04-04 2017-06-08 大正製薬株式会社 オキソ複素環誘導体
WO2015180060A1 (zh) 2014-05-28 2015-12-03 杭州普晒医药科技有限公司 一种二氮杂环庚烷化合物的盐及其晶型与无定型物
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
US20160051533A1 (en) 2014-08-20 2016-02-25 Ladd Research LLC Diagnosis and pharmacological treatment of seasonal affective disorder and symptoms of seasonality
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
AU2016295693B2 (en) 2015-07-17 2020-05-21 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
BR112018067906A2 (pt) 2016-03-10 2019-01-29 Janssen Pharmaceutica Nv métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
WO2020023723A1 (en) 2018-07-27 2020-01-30 Icahn School Of Medicine At Mount Sinai Method of treating aggression with orexin receptor antagonists
GB201820458D0 (en) 2018-12-14 2019-01-30 Heptares Therapeutics Ltd Ox1 antagonists

Also Published As

Publication number Publication date
HRP20191220T1 (hr) 2019-10-18
EP2491038B1 (en) 2016-04-06
TW201217377A (en) 2012-05-01
PE20110404A1 (es) 2011-07-08
AU2010310595B2 (en) 2015-07-16
RS54945B1 (sr) 2016-11-30
HRP20160781T1 (hr) 2016-09-23
CL2010001162A1 (es) 2011-04-08
NI201200062A (es) 2013-04-19
PH12012500796A1 (en) 2012-11-26
KR20170136645A (ko) 2017-12-11
PL2491038T3 (pl) 2016-10-31
EP3581575A1 (en) 2019-12-18
US8653263B2 (en) 2014-02-18
TR201910327T4 (tr) 2019-07-22
CA2778484C (en) 2018-07-31
IL219234A (en) 2015-02-26
EA022766B1 (ru) 2016-02-29
EP3093291B1 (en) 2019-05-08
TWI481613B (zh) 2015-04-21
AR078731A1 (es) 2011-11-30
DK3093291T3 (da) 2019-07-29
USRE48841E1 (en) 2021-12-07
CA2778484A1 (en) 2011-04-28
ME02437B (me) 2016-09-20
US9079911B2 (en) 2015-07-14
US20150335651A1 (en) 2015-11-26
PL3093291T3 (pl) 2019-11-29
IL219234A0 (en) 2012-06-28
JP2013508403A (ja) 2013-03-07
LT3093291T (lt) 2019-07-10
CY1121848T1 (el) 2020-07-31
PT2491038T (pt) 2016-07-14
AR114667A2 (es) 2020-09-30
US20240109901A1 (en) 2024-04-04
US20140179697A1 (en) 2014-06-26
EP3093291A1 (en) 2016-11-16
AU2015242975A1 (en) 2015-11-05
RS59004B1 (sr) 2019-08-30
SMT201600216B (it) 2016-08-31
SMT201900392T1 (it) 2019-09-09
US20210347781A1 (en) 2021-11-11
EP2491038A1 (en) 2012-08-29
NZ599629A (en) 2013-12-20
ME03452B (me) 2020-01-20
JOP20180019B1 (ar) 2023-09-17
JP5759470B2 (ja) 2015-08-05
CN102781942A (zh) 2012-11-14
AU2010310595A1 (en) 2012-05-17
EA201270591A1 (ru) 2012-11-30
KR101859409B1 (ko) 2018-05-18
WO2011050198A1 (en) 2011-04-28
US20120208812A1 (en) 2012-08-16
CY1117743T1 (el) 2017-05-17
SI3093291T1 (sl) 2019-08-30
ES2585806T3 (es) 2016-10-10
BR112012010820A2 (pt) 2016-04-05
MX2012004753A (es) 2012-09-07
US11667644B2 (en) 2023-06-06
KR20170135989A (ko) 2017-12-08
KR101859400B1 (ko) 2018-05-18
US20200048263A1 (en) 2020-02-13
SI2491038T1 (sl) 2016-08-31
CR20120273A (es) 2012-10-25
HUE043962T2 (hu) 2019-09-30
US20170129901A1 (en) 2017-05-11
UA107812C2 (xx) 2015-02-25
DK2491038T3 (da) 2016-07-18
HUE028650T2 (en) 2016-12-28
ECSP12011908A (es) 2012-07-31
US11059828B2 (en) 2021-07-13
CO6541572A2 (es) 2012-10-16
JO3267B1 (ar) 2018-09-16
JOP20180019A1 (ar) 2019-01-30
HK1175463A1 (zh) 2013-07-05
PT3093291T (pt) 2019-07-25
CN102781942B (zh) 2015-09-23
UY32966A (es) 2011-04-29
BR112012010820B1 (pt) 2021-09-14
KR20120105449A (ko) 2012-09-25
AU2015242975B2 (en) 2017-06-01
US12378254B2 (en) 2025-08-05
HK1231463A1 (en) 2017-12-22

Similar Documents

Publication Publication Date Title
US12378254B2 (en) Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US9586962B2 (en) Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
US8680275B2 (en) Fused heterocyclic compounds as orexin receptor modulators
HK1231463B (en) Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
HK1175463B (en) Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators